Showing 20 of 71 recruiting trials for “lymphocytic-mastitis”
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
👨⚕️ Jennifer A Woyach, MD, Ohio State University Comprehensive Cancer Center📍 3 sites📅 Started Jul 2023View details ↗
RecruitingNCT06203652 ↗
The Pathogenesis and Prognostic Factors of Lymphoma
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
👨⚕️ Mazyar Shadman, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started May 2023View details ↗
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Vaccine Responses in Patients With B Cell Malignancies
👨⚕️ Adrian U Wiestner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Sep 2022View details ↗
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
👨⚕️ Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company📍 144 sites📅 Started Jul 2022View details ↗
RecruitingNCT04785989 ↗
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
👨⚕️ Christopher Fletcher, MD, School of Medicine and Public Health, University of Wisconsin, Madison📍 1 site📅 Started Jun 2022View details ↗
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
👨⚕️ Barbara Eichhorst, MD, Prof., Department I of Internal Medicine, University Hospital Cologne📍 30 sites📅 Started Apr 2022View details ↗
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
👨⚕️ Daniel Ermann, MD, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Jan 2022View details ↗
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
👨⚕️ Natalie Grover, MD, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Nov 2020View details ↗
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →